Our strategies are designed to make essential medicines more affordable.

An effective and sustainable response to HIV, TB, Hepatitis C and COVID-19 cannot be achieved unless we tackle the overpricing of medicines.

For access to life-saving medicines to be equitable, we need increased competition and fair pricing.

Working in collaboration

Our work involves working closely with governments and patent offices, global development agencies and donors, to provide information on where their investment will have the most impact, and advocating for the pharmaceutical industry to stop price gouging, and ensure their access strategies are informed by communities.

Civil society organizations implement our work in middle-income countries, which have a dual burden of high prevalence and high prices. We support organizations so they are equipped to challenge intellectual property (IP) barriers in their country and region.